Moderna’s chief legal officer will retire in March under an agreement that provides US$1.63 million in fixed severance and up to US$8 million linked to litigation outcomes. The package also preserves her salary, benefits and equity vesting through her departure date.
- Chief Legal Officer Shannon Thyme Klinger to remain until March 31, 2027
- US$1.6283 million in salary and target-bonus severance
- Up to US$8 million tied to litigation involving Arbutus, Genevant, Pfizer and BioNTech
- COBRA healthcare premiums covered through September 2028, subject to conditions
Moderna’s chief legal officer is set to leave with a package worth up to US$9.63 million before healthcare costs, with the largest component dependent on the outcome of patent litigation involving major pharmaceutical rivals. Shannon Thyme Klinger will remain employed until March 31, 2027, under a transitional services and retirement agreement with Moderna (NASDAQ:MRNA).
Fixed Severance and Litigation-Linked Payments
Klinger’s fixed severance totals US$1.6283 million, representing 12 months of base salary plus her current annual target bonus. It will be paid in substantially equal fortnightly instalments over the year after her retirement date, subject to the agreement’s conditions.
The more unusual element is the potential additional payment. Klinger would receive US$2.5 million if Moderna prevails in current and related future proceedings involving Arbutus Biopharma and Genevant Sciences. A further amount of up to US$5.5 million depends on the result of Moderna’s current and related future litigation with Pfizer, BioNTech and related parties. The filing does not say how those payments would be calculated within the stated maximums, or when the relevant proceedings are expected to conclude.
Transition Period Extends Beyond Retirement Date
Until March 31, Klinger will continue receiving her current base salary and benefits, vesting in outstanding equity awards and remaining eligible for a 2026 performance bonus based on her target bonus multiplied by the board-determined corporate performance factor. Moderna can also require her to transition duties before the retirement date, and she will be deemed to have resigned from all officer roles on the earlier of that date or a company-designated date.
The company will pay Klinger’s COBRA premiums until September 30, 2028, although that support can end earlier if she becomes eligible for health coverage through another employer or loses COBRA eligibility. The filing does not disclose the expected cost of that coverage or identify Klinger’s successor.
Legal Leadership Change Comes Amid Pipeline Execution
The departure follows a stronger quarter for Moderna, which recently returned to GAAP profit and raised its 2026 revenue-growth outlook while advancing its melanoma programme. The retirement agreement does not state whether Klinger’s departure was previously planned, nor does it indicate a dispute between the executive and the company.
For shareholders, the immediate issue is less the fixed severance than the unusual bridge between an executive transition and litigation outcomes. The agreement puts a value on Klinger’s continued involvement while leaving as much as US$8 million exposed to court results that remain unresolved.
Bottom Line?
The next material questions are who will take over Moderna’s legal function and whether any litigation-linked payment ever becomes due.
Questions in the middle?
- Who will succeed Shannon Thyme Klinger as Moderna’s chief legal officer?
- What conditions in the full agreement govern the US$8 million of litigation-linked payments?
- When will the Arbutus, Genevant, Pfizer and BioNTech proceedings reach outcomes capable of triggering those payments?